RNS Number:9239Q
CeNeS Pharmaceuticals PLC
16 October 2003



   CeNeS announces appointment of Dr Peter Johnson as non-executive director


Cambridge, UK, 16th October 2003 - CeNeS Pharmaceuticals plc (LSE: CEN) today
announced the appointment of Dr Peter Johnson as a non-executive director of
CeNeS Pharmaceuticals plc ("CeNeS"). Dr Johnson has had extensive experience at
senior executive and non-executive level in a number of major pharmaceutical and
biotechnology companies and is currently Chairman of Oxford BioMedica plc and
Executive Chairman of Sterix Limited.


Commenting on the appointment, Alan Goodman, Chairman of CeNeS said, "I am
delighted to welcome Dr Johnson to the CeNeS Board. His extensive experience of
big pharma research and development and growing biotechnology companies will be
of great value to CeNeS as our development pipeline progresses into late stage
clinical development. This appointment is also another step forward for CeNeS as
the Company progresses its corporate development. The Board believe that CeNeS
is well positioned to deliver value to shareholders in the future."


For more information please contact:

CeNeS Pharmaceuticals plc

Neil Clark

Tel: +44 (0)1223 266466

Fax: +44 (0)1223 266467


Notes to Editors:


CeNeS is a biopharmaceutical company specialising in the development and
commercialisation of drugs for pain control. The company has development assets
targeting pain and has a portfolio of carried interests in assets that it has
divested. The company is based in Cambridge, England. For further information
visit www.cenes.co.uk.


Dr Peter Johnson, Ph.D., (67) has extensive R&D experience with five major
international pharmaceutical companies: Wellcome, Hoechst, SmithKline, Fisons
and Astra. He was formerly Chairman and Managing Director of SmithKline and
French Research Ltd and Group Main Board Director of R&D Worldwide for Fisons.
Formerly a Director of Proteus Molecular Design and Non-Executive Director and
Chairman of the Scientific Advisory Board of Quadrant Healthcare plc, he is
currently Chairman of Oxford BioMedica plc and Sterix Limited. Within the last
five years he was a non-executive director of Quadrant Healthcare Limited and
CBAMS Limited.


CeNeS confirms that no other details are required to be disclosed under
paragraph (f) of Schedule 2 of the AIM Rules with respect to Dr Johnson.






                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
BOAGUGCPUUPWGGA